DIA Annual Meeting 2014 Statistical Science and Quantitative Thinking Track AJ Sankoh, Rima Izem.

Slides:

Advertisements

Similar presentations

Patient Selection Markers in Drug Development Programs

Advertisements

Delete these guides from slide master before printing or giving to the client 1 Bayesian Trial Design – Case studies Panelists Andrew Mugglin, Medtronic.

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.

FDA/Industry Statistics Workshop 2005 Parallel Session 6: Vaccine Trials 10:10 am – 11:30 am, Sept. 16, 2005.

Panel Discussion 1 George Williams Amgen. Barbara Tilley - Sample Size Estimation… Key point – considering both short term benefit of symptomatic treatment.

Breakout Session 4: Personalized Medicine and Subgroup Selection Christopher Jennison, University of Bath Robert A. Beckman, Daiichi Sankyo Pharmaceutical.

The Statisticians Role in Pharmaceutical Development

Industry/FDA/Academia Safety Graphics Working Group Introduction and Overview FDA/QSPI Biostatistics, Statistical Programming, and Data Management Summit.

Impact of Dose Selection Strategies on the Probability of Success in the Phase III Zoran Antonijevic Senior Director Strategic Development, Biostatistics.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

David A H Whiteman MD FAAP FACMG Global Clinical Sciences Leader Shire Pharmaceuticals.

Norisuke Kawai Clinical Statistics, Pfizer Japan Inc.

Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.

Emerging Trends in Regulatory Biostatistics - What might be their impact ? Robert T. O’Neill Ph.D. Director, Office of Biostatistics Office of Translational.

Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.

Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014.

DATA MONITORING COMMITTEES: COMMENTS ON PRESENTATIONS Susan S. Ellenberg, Ph.D. Department of Biostatistics and Epidemiology University of Pennsylvania.

Planning the Lifecycle of Safety Evaluation

Study Session Experimental Design. 1. Which of the following is true regarding the difference between an observational study and and an experiment? a)

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Regulatory Affairs and Adaptive Designs Greg Enas, PhD, RAC Director, Endocrinology/Metabolism US Regulatory Affairs Eli Lilly and Company.

Pharmacists Perceptions of the Development of Herbal Medicines in Iran

 Getting Outside of the Box: Designing and Implementing Innovative Ways to Prevent Infection Willo Pequegnat, Ph.D., Salix Health Consulting/USAID Susan.

Robert Gordon Biostatistics and Medical Safety Johnson & Johnson

Graphical Approaches for Safety Signal Detection Efforts of the FDA-Industry-Academia Working Group Mat Soukup, Ph.D. Acting Team Lead Biometrics 7, CDER.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

European Patients’ Academy on Therapeutic Innovation Principles of New Trial Designs.

NIAMS Extramural Scientific Planning Retreat 2013 April 4, 2013 Session 1: Strategies for Successful Rare Disease Clinical Trials.

Robert Gordon FDA/QSPI Biostatistics, Statistical Programming and Data Management Summit Washington D.C. March 2012.

Cognition as an Under- Explored Aspect of Multiple Disorders Richard Keefe, PhD Professor of Psychiatry & Behavioral Sciences and Psychology Duke University.

Rosemarie Bernabe, PhD Julius Center for Health Sciences and Primary Care Patient representatives’ contributions to the benefit-risk assessment tasks of.

Topic #1: EOP2A Meetings Please comment on the goals of the proposed EOP2A meeting and the impact that such meetings could have on optimizing dose selection.

1 DIA Global Statistics Community Global Head: Jerry Schindler China: William (Bill) Wang Europe: Jürgen Kübler North America: Joan Buenconsejo.

THE CASE FOR BAYESIAN METHODS IN BENEFIT-RISK ASSESSMENT: OVERVIEW AND FUTURE DIRECTIONS 19 MAY 2016 / CARL DI CASOLI (BAYER) / MARIA COSTA (GSK, UK) /

Impact of Adaptive Design on Modern Drug Development.

© 2016 Global Market Insights, Inc. USA. All Rights Reserved U.S. Pharmacovigilance Market to grow at 10.7% CAGR from 2016 to 2024.

Is a Clinical Trial Right for Me?

Efficacy and Safety of Medicines

Patient Focused Drug Development An FDA Perspective

FDA Division of Cardiovascular Devices

DIA Virtual Journal Club Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials Discussant Susan.

NCI Epidemiology and Genomics Research Program

Industry Perspective: Expanded Access Programs

Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions

Overview of Adaptive Design

Statistical Approaches to Support Device Innovation- FDA View

DIA BSWG © 2015 DIA, Inc. All rights reserved..

Annual Business Meeting & Class of 2017 Fellows

Innovative Approaches to Clinical Trials

Regulatory perspective

Is a Clinical Trial Right for Me?

DIA Bayesian Scientific Working Group 2018 Annual Meeting

Valerie Durkalski Medical University of South Carolina

Use of Real-World Data in Clinical Drug Development

Greetings from 1st EFSPI regulatory workshop

Issues in Hypothesis Testing in the Context of Extrapolation

Data Monitoring committees and adaptive decision-making

Type and impact of HTA-related scientific advice given during development The variability in HTA organisations and methodologies that are utilised in HTA.

Subteam: Expedited Approvals Chairs: Bob Campbell, Larry Gould

Roger J. Lewis, MD, PhD Department of Emergency Medicine

Registration is Open:

JSM 2018 A Case Study on Model Based Meta Analysis (MBMA) for Drug Development Decisions Guohui Liu, Zhaoyang Teng, Zoe Hua, Neeraj Gupta, Karthik Venkatakrishnan,

Optimal Basket Designs for Efficacy Screening with Cherry-Picking

Stat4Onco Annual Symposium Zhenming Shun April 27, 2019

The 3rd Stat4Onc Annual Symposium

David Manner JSM Presentation July 29, 2019

Finding a Balance of Synergy and Flexibility in Master Protocols

Oncology Biostatistics

Presentation transcript:

DIA Annual Meeting 2014 Statistical Science and Quantitative Thinking Track AJ Sankoh, Rima Izem

Session TitleSpeakers Design and Sample Size Planning for Multiregional Clinical Trials Jim Hung; Zhaoyang Teng; Gordon Lan Strategic Quantitative Thinking: Designing a Roadmap for Innovation Jim Hung; Rima Izem; Lisa LaVange; Karen Price; Ram Tiwari, Lilly Yue; Tom Permutt Mitigating Missing Data in Clinical Trials: Moving Toward Global Behavioral Change Impacts Efficacy, Safety and Quality Carol Robertson-Plouch; Tom Permutt; Joshua Betcher Impact of Bayesian Methods in Drug Development with Focus on Comparative Effectiveness Research Brad Carlin; Ram Tiwari; Matthew Rotelli Predictive Enrichment: Design, Development Strategies, and Methodological Issues Zoran Antonijevic; Robert Beckman; Sue-Jane Wang Key Subgroup Analysis Issues in Clinical Trials David Ohlssen; Lilly Yue; Ilya Lipkovich Continued in next slide

Session TitleSpeakers Your Future Success as a Master’s Level Statistician: Learn from the Past of These Industry Masters Luke Hickey; Matthew Downs; Kristine Broglio; Barbara Day Seeing is Believing! Good Graphic Design Principles for Medical Research Susan Duke; Brenda Crowe; Richard Forshee Separating Perceptions from Reality in Regards to the Acceptance of Adaptive Trials by Regulatory Agencies Lisa LaVange; Silke Jorgens; Vladimir Dragalin Exploring Bayesian Approaches Applied to New Treatments for Rare Diseases John Troiani; Scott Berry; Kit Roes Benefit/Risk Evaluation in Drug Development George Quartey; Andreas Sashegyi; Qi Jiang Pediatrics Trials: Improvements through Bayesian methods, Adaptive Design, and Modeling/Simulation Scott Berry; Freda Cooner; Brenda Cirincione Moving Beyond the Traditional Psychometric Validation of New Phase 3 Clinical Outcome Assessments Rima Izem; Cheryl Coon; Laura Lee Johnson